On 1 March 2012, the European Commission presented a proposal to speed up the market entry of new medicines. The proposal establishes deadlines for decisions on matters of medicines pricing and reimbursement. Meeting these deadlines is subject to stringent control measures.
The new draft Directive represents an important simplification measure and revokes the previous Transparency Directive dating back to 1989, which no longer reflected the increased complexity of pricing and reimbursement procedures.
This follows from a consultation to which EPHA participated.
With its proposal, the Commission aims to streamline and reduce the duration of national decisions on pricing and reimbursement of medicines. In the future, the European Commission proposes that decisions should be taken within 120 days for innovative medicines, and for generic medicinal products within 30 days (compared to 180 days today). The Commission also proposes strong enforcement measures in case decisions do not comply with these time limits as they are often exceeded by Member States.
The transparency of the authorization procedures for medicinal products on the market has been a long-standing focus of attention by the Commission but the old directive needed some reinforcement with respect to deadlines for decisions on matters of pricing and reimbursement. Studies have shown that delays have been experienced for up to 700 days for innovative medicines and up to 250 days for generics.
With its revision – a follow-up to the conclusion of the 2009 Commission report on the pharmaceutical sector (Pharmaceutical Sector Inquiry) – the Commission proposal aims to achieve the following:
– Guaranteeing shorter time limits for national, regional or local decisions on pricing and reimbursement;
– Strong enforcement measures;
– Obligation for Member States to regularly reporting on their decisions and the time involved;
– Notifying national pricing and reimbursement draft measures to the Commission;
– Ensuring legal clarity and consistency; and
– Addressing the uncertainties relating to innovative pricing and reimbursement procedures.
Next steps
The draft proposal from the European Commission will now be debated by the European Parliament and the Council of Ministers who will have to decide on the final Directive.
—–
EPHA related articles
– [->4967]
– [->4597]
– [->3976]
– [->4910]
– [->4256]
